Prognostic significance of extranodal microscopic foci discontinuous with primary lesion in rectal cancer

1998 ◽  
Vol 41 (1) ◽  
pp. 55-61 ◽  
Author(s):  
Hideki Ueno ◽  
Hidetaka Mochizuki ◽  
Shoetsu Tamakuma
Keyword(s):  
Rectal Cancer ◽  
Prognostic Significance ◽  
Primary Lesion

Prognostic significance of apical lymph node metastasis in patients with node-positive rectal cancer

2012 ◽  
Vol 15 (1) ◽  
pp. e13-e20 ◽  
Author(s):  
J. Peng ◽  
H. Wu ◽  
X. Li ◽  
W. Sheng ◽  
D. Huang ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Prognostic Significance ◽  
Node Metastasis ◽  
Node Positive

scholarly journals Prognostic significance of expression of protein p53 in rectal cancer patients treated

Onkologie ◽  
2016 ◽  
Vol 10 (5) ◽  
pp. 228-230
Author(s):  
David Buka ◽  
Josef Dvořák ◽  
Veronika Sitorová ◽  
Igor Richter ◽  
Igor Sirák ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Cancer Patients ◽  
Prognostic Significance ◽  
Protein P53

scholarly journals Prognostic Significance of EMVI in Rectal Cancer in a Tertiary Cancer Hospital in India

2021 ◽  
Author(s):  
Sayali Y. Pangarkar ◽  
Akshay D. Baheti ◽  
Kunal A. Mistry ◽  
Amit J. Choudhari ◽  
Vasundhara R. Patil ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Distant Metastasis ◽  
Locally Advanced ◽  
Prognostic Significance ◽  
Signet Ring Cell ◽  
Poor Prognostic Factor ◽  
Free Survival ◽  
Signet Ring ◽  
Rectal Cancers ◽  
Ring Cell

Abstract Background Presence of extramural venous invasion (EMVI) is a poor prognostic factor for rectal cancer as per literature. However, India-specific data are lacking. Aim The aim of the study is to determine the prognostic significance of EMVI in locally advanced rectal cancer on baseline MRI. Materials and Methods We retrospectively reviewed 117 MRIs of operable non-metastatic locally advanced rectal cancers in a tertiary cancer institute. Three dedicated oncoradiologists determined presence or absence of EMVI, and its length and thickness, in consensus. These patients were treated as per standard institutional protocols and followed up for a median period of 37 months (range: 2–71 months). Kaplan-Meier curves (95% CI) were used to determine disease-free survival (DFS), distant-metastases free survival (DMFS), and overall survival (OS). Univariate analysis was performed by comparing groups with log-rank test. Results EMVI positive cases were 34/114 (29%). More EMVI-positive cases developed distant metastasis compared with EMVI-negative cases (14/34–41% vs. 22/83–26%). The difference, however, was not statistically significant (p = 0.146). After excluding signet-ring cell cancers (n = 14), EMVI showed significant correlation with DMFS (p = 0.046), but not with DFS or OS. The median thickness and length of EMVI was 6 and 14 mm, respectively in patients who developed distant metastasis, as compared with 5 and 11 mm in those who did not, although this difference was not statistically significant. Conclusion EMVI is a predictor of distant metastasis in locally advanced non-metastatic, non-signet ring cell rectal cancers. EMVI can be considered another high-risk feature to predict distant metastasis.

scholarly journals SPAR – a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Michael B. Jameson ◽  
Kirsten Gormly ◽  
David Espinoza ◽  
Wendy Hague ◽  
Gholamreza Asghari ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Prognostic Score ◽  
Prognostic Significance ◽  
Rectal Adenocarcinoma ◽  
Trial Registration ◽  
Tumour Regression ◽  
Preoperative Treatment ◽  
Ordered Categories ◽  
Pelvic Mri ◽  
Link Type

Abstract Background Retrospective studies show improved outcomes in colorectal cancer patients if taking statins, including overall survival, pathological response of rectal cancer to preoperative chemoradiotherapy (pCRT), and reduced acute and late toxicities of pelvic radiation. Major tumour regression following pCRT has strong prognostic significance and can be assessed in vivo using MRI-based tumour regression grading (mrTRG) or after surgery using pathological TRG (pathTRG). Methods A double-blind phase 2 trial will randomise 222 patients planned to receive long-course fluoropyrimidine-based pCRT for rectal adenocarcinoma at 18+ sites in New Zealand and Australia. Patients will receive simvastatin 40 mg or placebo daily for 90 days starting 1 week prior to standard pCRT. Pelvic MRI 6 weeks after pCRT will assess mrTRG grading prior to surgery. The primary objective is rates of favourable (grades 1–2) mrTRG following pCRT with simvastatin compared to placebo, considering mrTRG in 4 ordered categories (1, 2, 3, 4–5). Secondary objectives include comparison of: rates of favourable pathTRG in resected tumours; incidence of toxicity; compliance with intended pCRT and trial medication; proportion of patients undergoing surgical resection; cancer outcomes and pathological scores for radiation colitis. Tertiary objectives include: association between mrTRG and pathTRG grouping; inter-observer agreement on mrTRG scoring and pathTRG scoring; studies of T-cell infiltrates in diagnostic biopsies and irradiated resected normal and malignant tissue; and the effect of simvastatin on markers of systemic inflammation (modified Glasgow prognostic score and the neutrophil-lymphocyte ratio). Trial recruitment commenced April 2018. Discussion When completed this study will be able to observe meaningful differences in measurable tumour outcome parameters and/or toxicity from simvastatin. A positive result will require a larger RCT to confirm and validate the merit of statins in the preoperative management of rectal cancer. Such a finding could also lead to studies of statins in conjunction with chemoradiation in a range of other malignancies, as well as further exploration of possible mechanisms of action and interaction of statins with both radiation and chemotherapy. The translational substudies undertaken with this trial will provisionally explore some of these possible mechanisms, and the tissue and data can be made available for further investigations. Trial registration ANZ Clinical Trials Register ACTRN12617001087347. (www.anzctr.org.au, registered 26/7/2017) Protocol Version: 1.1 (June 2017).

scholarly journals EP-1926 Radiomics in rectal cancer: prognostic significance of 3D features extracted from diagnostic MRI

2019 ◽  
Vol 133 ◽  
pp. S1048
Author(s):  
C. Piazzese ◽  
P. Whybra ◽  
E. Qasem ◽  
D. Harris ◽  
R. Gtaes ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Prognostic Significance

The prognostic significance of stapler doughnuts’ examination at low anterior resection for rectal cancer

2017 ◽  
Vol 32 (8) ◽  
pp. 1233-1234
Author(s):  
Eleftherios Spartalis ◽  
Demetrios Moris ◽  
Antonios Athanasiou ◽  
Stylianos Kykalos ◽  
Dimitrios Dimitroulis
Keyword(s):  
Rectal Cancer ◽  
Anterior Resection ◽  
Low Anterior Resection ◽  
Prognostic Significance

Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels

2020 ◽  
pp. 1-6
Author(s):  
Daxin Huang ◽  
Qingliang Lin ◽  
Jianyuan Song ◽  
Benhua Xu
Keyword(s):  
Rectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Prognostic Value ◽  
Locally Advanced ◽  
Prognostic Significance ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Carbohydrate Antigen ◽  
Curative Surgery ◽  
Pretreatment Serum

<b><i>Background:</i></b> Elevated pretreatment carcinoembryonic antigen (CEA) levels are related to poor prognosis in patients with locally advanced rectal cancer (LARC) treated with neo-CRT followed by TME. In patients with normal pretreatment CEA levels, the prognostic significance of carbohydrate antigen 199 (CA199) is controversial. <b><i>Objectives:</i></b> The aim of this study was to explore the prognostic value of pretreatment serum CA199 in patients with LARC who had normal pretreatment CEA levels treated with neo-CRT followed by curative surgery. <b><i>Methods:</i></b> A retrospective study of 456 patients with LARC treated with neo-CRT followed by TME between January 2006 and May 2017 was performed. We employed the maximal χ<sup>2</sup> method to determine the CA199 threshold of 9.1 U/mL based on the difference in survival and divided patients into 2 groups. Group 1: patients with pretreatment s-CEA &#x3c; 5 ng/mL and CA199 ≥ 9.1 U/mL. Group 2: patients with pretreatment s-CEA &#x3c; 5 ng/mL and CA199 &#x3c; 9.1 U/mL. Overall survival (OS) across CA199 was assessed using Cox proportional hazard regression models (PS:CEA ≥ 5 ng/mL was seen as elevated). <b><i>Results:</i></b> Multivariate analyses demonstrated that the following factors were significantly related to OS in patients with LARC with normal pretreatment CEA levels: ypT (odds ratio [OR] 1.863, <i>p</i> = 0.030), ypN (OR 1.622, <i>p</i> = 0.026), and pretreatment CA199 levels (OR 1.886, <i>p</i> = 0.048). <b><i>Conclusion:</i></b> Pretreatment CA199 is an independent factor for OS in patients with LARC with normal pretreatment CEA levels, which may reach the clinic to guide individualized decision-making.

Sign in / Sign up

Export Citation Format

Share Document